FREQUENCY THERAPEUTICS, INC. (FREQ) News
Filter FREQ News Items
FREQ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FREQ News Highlights
- For FREQ, its 30 day story count is now at 4.
- Over the past 9 days, the trend for FREQ's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about FREQ are PRE.
Latest FREQ News From Around the Web
Below are the latest news stories about FREQUENCY THERAPEUTICS INC that investors may wish to consider to help them evaluate FREQ as an investment opportunity.
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical ResultsLEXINGTON, Mass., November 17, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it will host a virtual investor event on December 13, 2022, with a focus on FX-322, the Company’s lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical r |
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial ResultsLEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022. “This past quarter has been one of momentum and execution. With the completion of enrollment for the Phase 2b study of our lead therapeutic candidate, FX-322, we are now pre |
Frequency Therapeutics GAAP EPS of -$0.55Frequency Therapeutics press release (FREQ): Q3 GAAP EPS of -$0.55.Cash, cash equivalents and marketable securities as of September 30, 2022, were $99.3 millionBased on current plans… |
FREQ stock climbs as Baird initiates at Outperform ahead of key readout (NASDAQ:FREQ)Frequency Therapeutics (FREQ) added ~16% Wednesday after Baird initiated coverage on the clinical-stage biotech with an Outperform recommendation noting an upcoming mid-stage readout… |
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing LossLEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show improvement in a pre-specified measure of s |
Frequency Therapeutics to Participate in September Investor and Medical ConferencesLEXINGTON, Mass., August 30, 2022--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that members of its management team will participate in investor and medical conferences later this month. |
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial ResultsLEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the second quarter ended June 30, 2022. “I am very pleased with our team’s pipeline execution and the clear progress across all of our clinical and pre-clinical programs. We have reached a predictable cadence in our F |
Frequency Therapeutics GAAP EPS of -$0.61 (NASDAQ:FREQ)Frequency Therapeutics press release (FREQ): Q2 GAAP EPS of -$0.61.Cash, cash equivalents and marketable securities as of June 30, 2022, were $111.0 million (excluding restricted cash). |
Gainey McKenna & Egleston Investigates The Officers And Directors Of Frequency Therapeutics, Inc. (FREQ)NEW YORK, July 08, 2022 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that it is investigating the officers and directors of Frequency Therapeutics, Inc. (“Frequency” or the “Company”) (NASDAQ: FREQ) for potential breaches of fiduciary duties, waste of corporate assets, and unjust enrichment between November 16, 2020 and March 22, 2021. |
Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past weekFrequency Therapeutics, Inc. ( NASDAQ:FREQ ) shareholders will doubtless be very grateful to see the share price up 41... |